BofA analyst Derik de Bruin downgraded Agilent to Neutral from Buy with a price target of $133, up from $130. Shares are up about 13% since the company reported Q4 results on November 20, and valuation appears full, the analyst tells investors in a research note. The firm thinks additional upside is likely limited given the lack of visibility across the life sciences tools market.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on A: